Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative
symbol logo$BCRX Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $0.31 up 1450.00% YoY • Reported revenue of $218.25M up 33.61% YoY • BioCryst Pharmaceuticals maintained its full year 2026 ORLADEYO revenue guidance of $625 million to $645 million and increased its total revenue guidance to a range of $690 million to $715 million.
1
5

Price since post

Full Details
MattressMonkey007
… actually I was watching matters unfold, thinking all was quite “material information” and wondering why the company did not PR it.

Advertisement|Remove ads.